Login
$BLSM
$13.65 -$0.37 (2.64%) Live

Ownership

13F as of Q2 2026 · 18.6M shares outstanding

Who owns BLSM?

By type of holder
Institutions 0.0% Insiders 96.0% Everyone else 4.0%
Concentration Top 10 holders own 142.6%
Cui Jingrong Jean 21.4% · Li Yishan 21.4%
Institutional ownership
0.0%
0.0 pts vs last qtr
Institutional holders
0
0 vs last qtr
Net shares bought
0
by institutions in Q2 2026
New / sold out
0 / 0
positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

No 13F manager has reported this stock in the last 8 quarters.

Biggest buyers in Q2 2026

None.

Biggest sellers in Q2 2026

None.

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for BlossomHill Therapeutics, Inc. in the last 12 months.

Is your stake being diluted?

There are not yet two fiscal years of reported share counts for BlossomHill Therapeutics, Inc..

How patient are the owners?

No 13F manager reports holding BLSM.

Super Investors

Investment managers reporting BLSM on Form 13F
No 13F manager reports holding BLSM yet.

Institutional Funds

Mutual funds and ETFs reporting BLSM on Form N-PORT; together they hold 2.5% of the company
SB
Fidelity Select Portfolios
Position value
$6.36M
% of company
1.87%
% of the fund
0.10%
As of
August 31, 2026
MS
Columbia Funds Series Trust I
Position value
$1.35M
% of company
0.40%
% of the fund
0.12%
As of
August 31, 2026

7 more funds behind a free account

See every fund holding BlossomHill Therapeutics, Inc. and how much of the fund the position is.

Sign up free

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G
CJ
Cui Jingrong Jean
Insider
Shares
4.0M
% of company
21.41%
Change vs last qtr
—
Held since
—
LY
Li Yishan
Insider
Shares
4.0M
% of company
21.41%
Change vs last qtr
—
Held since
—

14 more holders behind a free account

See every insider and 5%+ holder of BlossomHill Therapeutics, Inc..

Sign up free

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support